← Back to news
Y

Yahoo Finance

Nasdaq Futures Fall Ahead of Busy Week

Y

PepsiCo rebrands Sunbites with fibre focus

Y

Freshworks Falls 60% in a Year as $7.5 Million Sale Shrinks Stake to 3.1% of This Portfolio's Assets

Y

Better Oil Stock: ConocoPhillips vs. Diamondback Energy

Y

This $130 Stock Could Be Your Ticket to Millionaire Status

Y

Air Lease Stock Up 43% as Investor Trims $6.9 Million Stake Despite $1 Billion Profit Year

Y

1 Boring ETF That Could Turn $100 Per Month Into $20,500

Y

Leveraged ETFs Are Aggressive by Design. Here's What That Means for Investors

Y

New tax rules are in effect this season—and many filers don’t know about them

Y

What Are Wall Street Analysts' Target Price for CoStar Group Stock?

Y

Five9 Stock Down 60% This Past Year, but One Investor Just Lifted Stake With $3.5 Million Buy

Y

Cisco's AI Orders Hit $2.1 Billion in One Quarter--And Two Major Products Aren't Even Counted Yet

Y

Pale Fire Capital Bets Big on Healthcare With a 2.07 Million Share Baxter International (BAX) Investment

Y

Ares Management CEO Sees Strong 2026 Deal Pipeline, Details AI Strategy at BofA Conference

Y

Prediction: These 3 Stocks Will Crush the Market in 2026

Y

They Make $500K A Year And Still Live Paycheck-To-Paycheck. 'America's Going, I Wouldn't Know How To Spend $40,000 A Month If You Gave It To Me'

Y

Freshworks Stock Down 60% in One Year as Revenue Jumps 16% and One Investor Sells $7 Million in Shares

Y

4 No-Brainer Semiconductor Stocks to Buy Right Now

Y

Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too?

Y

Ackman’s $2B Bet: Why Smart Money is Backing Up the Truck on “Deeply Discounted” Meta Stock

Y

JPMorgan builds $2.93 billion stake in health care stock

Y

Estes Logistics expands with Key Trucking acquisition

Y

Has Chinese light vehicle demand peaked?

Y

Goldman Sachs sends harsh warning to U.S. credit card users

Y

Michael Burry made $100M by betting against the housing market in 2008, now he’s set his sights on AI with these moves

Y

BILL Stock Down 24%, Core Revenue Up 17%: Why a 14% Portfolio Bet Signals Conviction

Y

California gas prices surge 40 cents in just 2 weeks as impact of refinery closures weighs

Y

Chemed Stock Down 15% in a Year as One Fund Builds a $5.56 Million Stake

Y

3 Dirt Cheap Stocks to Buy With $1,000 Right Now

Y

Billionaire BlackRock CEO Larry Fink Says 'Almost No One Is Close' To Saving The Nearly $2.1M Americans Claim They Need For A Comfortable Retirement

Y

Trump Declares 'Largest Tax Refund Season Ever' In 2026: 'One Big Beautiful Bill' Secures Everything Needed Until 2030

Y

Vitalik Buterin: Hedging on Prediction Markets Could 'Replace Fiat Currency'

Y

Up 50% in One Year: Why a Fund Cut $5 Million in TriMas Stock but Held Onto a 3% Position

Y

Metaplanet Posts $605 Million Loss After Spending Billions on Bitcoin

Y

Intel Stock Has Gotten Way Ahead of Lip-Bu Tan's Turnaround Plans. Will Investors Regret Buying?

Y

Real Estate Rebound? The 3X Play for Investors Betting on a Commercial Property Pivot

Y

What Makes BioMarin (BMRN) so Attractive

Y

Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough

Y

FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)

Y

Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance

Y

FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT)

Y

Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)

Y

Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program

Y

Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry

Y

Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

Y

Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating

Y

Here is Why Beam Therapeutics (BEAM) Appears so Attractive

Y

Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)

Y

Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)

Y

Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026

Y